Another ALK inhibitor (#ensartinib) gets FDA approval eXalt3 study:

- 1L, Ph III, ALK+ mNSCLC vs Crizotinib
- Ensartinib vs crizotinib (NR vs 12.7mos, HR: 0.45)
- CNS ORR 64% w/ ensartinib vs 21%
- AES: rash, 💪 pain, nausea

#OncSky #MedSky #lcsm #CanSky